Finally, we demonstrate that targeting sPLA2 or cPLA2 may be a novel approach for treatment of psoriasis and other inflammatory skin diseases characterized by epidermal hyperplasia and epidermal inflammatory responses. The gene discussed is PLA2G2A; the disease is inflammatory skin disease.